Nipent (pentostatin)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Pentostatin is an antineoplastic antibiotic produced by Streptomyces antibioticus.
USES: Pentostatin is used to treat a certain type of cancer (hairy cell leukemia). It works by slowing or stopping the growth of cancer cells.
Generic name: pentostatin
Pronunciation: (PEN-toe-STAT-in)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Nipent
Indications
The following indications are listed for Nipent:
- Hairy Cell Leukemia
Dosing
In patients with an elevated predose serum creatinine concentration, the dose of pentostatin should be withheld and creatinine clearance determined. The manufacturer states that there are insufficient data to recommend an initial or subsequent dose of pentostatin in patients with impaired renal function (i.e., creatinine clearance less than 60 mL/minute). Since patients with renal failure may be at increased risk for toxicity, they should receive pentostatin only when the potential benefits justify the possible risks; 2 patients with creatinine clearances of 50-60 mL/minute achieved complete responses without unusual toxicity when treated with 2 mg/m2 of pentostatin.
Withholding or discontinuing one or more individual doses may be required in patients who experience severe adverse reactions with pentostatin therapy.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Pentostatin can cause fetal harm when administered to pregnant women, but potential benefits from use of the drug may be acceptable in certain conditions despite possible risks to the fetus. There are no adequate and controlled studies of the drug in pregnant women; however, pentostatin produced both maternal and fetal (teratogenic) toxicity in animal studies at dosages approximating those currently recommended in humans. Women of childbearing potential should be advised to avoid becoming pregnant while receiving pentostatin, and the drug should be used during pregnancy only in life-threatening situations or severe disease for which safer drugs cannot be used or are ineffective. If pentostatin is administered during pregnancy or if the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus.
It is not known whether pentostatin is distributed into milk. Because of the potential for serious adverse reactions to pentostatin in nursing infants if the drug were distributed into milk, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.